Malignant neoplasm of other endocrine glands and related structures
Chapter 2:Neoplasms
ICD-10 C75 is a billable code used to indicate a diagnosis of malignant neoplasm of other endocrine glands and related structures.
C75 refers to malignant neoplasms that arise from various endocrine glands not specifically categorized under other codes. This includes tumors originating from glands such as the adrenal glands, thyroid gland, parathyroid glands, and other related structures. These neoplasms can disrupt normal hormone production, leading to significant metabolic disturbances. Symptoms may vary widely depending on the gland affected and the hormones involved. For instance, adrenal tumors may lead to excess cortisol production, resulting in Cushing's syndrome, while thyroid malignancies can cause hyperthyroidism or hypothyroidism. Diagnosis typically involves imaging studies, biopsy, and laboratory tests to assess hormone levels. Treatment often includes surgical resection, radiation therapy, and chemotherapy, depending on the tumor's type and stage. Accurate coding is crucial for appropriate treatment planning and reimbursement.
Detailed clinical notes on hormone levels, imaging results, and biopsy findings.
Diagnosis and management of adrenal tumors, thyroid cancers, and parathyroid malignancies.
Endocrinologists must document hormone function tests and any metabolic implications of the neoplasm.
Comprehensive treatment plans, including surgical notes, chemotherapy regimens, and follow-up care.
Management of patients undergoing treatment for endocrine malignancies.
Oncologists should ensure clear documentation of tumor staging and response to treatment.
Used when a biopsy is performed to confirm malignancy.
Pathology report must clearly indicate malignancy.
Endocrinologists and oncologists must ensure accurate coding based on pathology findings.
C75 includes malignant neoplasms of various endocrine glands not specifically categorized elsewhere, such as adrenal, thymus, and other related structures.
